Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KLF5 on dexamethasone-mediated atrophy in mouse satellite cells

ABSTRACT: KLF5 on dexamethasone-mediated atrophy in mouse satellite cells

PROVIDER: PRJNA693183 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13482438.fastq.gz	Fastqsanger.gz
	SRR13482439.fastq.gz	Fastqsanger.gz
	SRR13482440.fastq.gz	Fastqsanger.gz
	SRR13482441.fastq.gz	Fastqsanger.gz
	SRR13482442.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Analysis of effects of KLF5 on dexamethasone-mediated atrophy in mouse satellite cells [RNA]

Project description:Analysis of effects of KLF5 on dexamethasone-mediated atrophy in mouse satellite cells [RNA]

| PRJNA693186 | ENA

Analysis of effects of KLF5 on dexamethasone-mediated atrophy in mouse satellite cells [RNA]

Project description:We analyzed effects of dexamethasone (Dex) on primary satellite cells (SCs) purified from control and MCK-Cre:Klf5f/f mice.

2021-08-31 | GSE165071 | GEO

Analysis of accessible chromatin regions in response to dexamethasone mediated-atrophy in mouse satellite cells [ATAC]

Project description:We analyzed the accessible chromatin regions globally in response to dexamethasone in primary mouse satellite cells (SCs)

2021-08-31 | GSE165070 | GEO

Analysis of accessible chromatin regions in response to dexamethasone mediated-atrophy in mouse satellite cells [ATAC]

Project description:Analysis of accessible chromatin regions in response to dexamethasone mediated-atrophy in mouse satellite cells [ATAC]

| PRJNA693182 | ENA

KLF5 on dexamethasone-mediated atrophy in mouse satellite cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-08-31 | GSE165072 | GEO

Induction of muscle atrophy by tumor and dexamethasone regulates a distinct set of proteins from atrophy caused by aging

Project description:To assess changes in the muscle proteome that due to tumor burden and dexamethasone treatments and compare proteomic changes that occur in atrophy due to tumor burden and dexamethasone treatment with atrophy caused by aging. Regulators of muscle atrophy induced by diseases such as cancer or drugs such as dexamethasone are largely unknown. We would therefore like to determine the proteomic signature of atrophying muscle caused by tumor burden (LLC cell injected mice) and dexamethasone treatment in order to examine possible biomarkers and regulators of muscle atrophy. We would also like to compared the proteomic signature of different modes of muscle atrophy to determine similarities and differences in the possible biomarkers and regulators.

2022-02-22 | PXD027490 | Pride

Differentiation and Dexamethasone Atrophy on C2C12 myotubes

Project description:Skeletal muscle atrophy and weakness are major contributors to morbidity, prolonged recovery, and long-term disability across a wide range of diseases. Atrophy is caused by breakdown of sarcomeric proteins resulting in loss of muscle mass and strength. Molecular mechanism underlying the onset of muscle atrophy and its progression have been analysed in patients, mice, and cell culture but the complementarity of these model systems remains to be explored. Here, we applied deep-coverage transcriptomic and proteomic profiling to characterize dynamic changes during dexamethasone-induced atrophy in the widely used murine skeletal muscle cell line C2C12. Comparison with published datasets confirmed that muscle differentiation is well recapitulated in C2C12 myotubes. Under dexamethasone-induced treatment, this model was particularly suited to capture early atrophy events, prior to disassembly and degradation of sarcomeric proteins. We also identified alterations in mitochondrial gene expression and differential alternative splicing events during early-stage myotube atrophy. This dataset complements existing in vivo data and provides novel insights into the regulatory processes during skeletal muscle wasting.

2025-09-29 | GSE300503 | GEO

Differentiation and Dexamethasone Atrophy on C2C12 myotubes

Project description:Differentiation and Dexamethasone Atrophy on C2C12 myotubes

| PRJNA1281074 | ENA

Deep Coverage Multi-omic Profiling of C2C12 Dexamethasone Skeletal Muscle Atrophy

2025-10-14 | PXD064871 | Pride

Transcriptome profiling of THSG treatment in a dexamethasone-induced muscle atrophy model using C2C12 myotubes

Project description:This study investigates the effects of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG) on gene expression changes in C2C12 myotubes under dexamethasone-induced muscle atrophy conditions. Using RNA-seq, we identified transcriptomic alterations associated with THSG treatment, aiming to elucidate its potential protective role against muscle atrophy.

2025-04-09 | GSE293772 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data